Results 61 to 70 of about 82,766 (300)

Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction

Advanced Healthcare Materials, EarlyView.
Atherosclerosis management is hindered by poor drug targeting and plaque heterogeneity. Nanotechnology overcomes these barriers via three core strategies: (1) target‐engineered nanocarriers that achieve lesion‐specific precision via ligand modification, biomimetic camouflage, stimuli‐responsive release, and self‐propelling nanomotors; (2) catalytic ...
Yuqi Yang, Jingguo Qu, Tonghuan Xiao, Xinyang Han, Michael Tin‐Cheung Ying   +4 more
wiley   +1 more source

Gender differences in the implementation of cardiovascular prevention measures after an acute coronary event [PDF]

, 2010
Objective To compare gender-related lifestyle changes and risk factor management after hospitalisation for a coronary event or revascularisation intervention in Europe.
C. Prugger, D. De Bacquer, G. De Backer, J. Dallongevillle, J. Heidrich, K. Kotseva, M. Montaye, null null, P. Amouyel   +8 more
core   +2 more sources

Selective Inhibition of Integrin β3 Topology Provides a Safer Antithrombotic Strategy

Advanced Science, EarlyView.
Current integrin αIIbβ3 inhibitors effectively reduce thrombosis but also increase bleeding risk. During thrombosis, high shear blood flow can directly activate the integrin αIIbβ3 via a distinct topological change in the β3 transmembrane domain, independent of hemostatic platelet signaling.
Joonha Lee, Chul‐Gyun Lim, Pothiappan Vairaprakash, Jong‐Min Kim, Jiyoon Kim, Ji‐Young Park, Klaus M. Hahn, Hyunbo Shim, Hae Woong Choi, Tobias S. Ulmer, Soon Jun Hong, Chungho Kim   +11 more
wiley   +1 more source

Research progress of new antiplatelet drugs in the prevention and treatment for ischemic stroke

Chinese Journal of Contemporary Neurology and Neurosurgery, 2013
Nowadays, antiplatelet drugs are still the routine medication in the acute phase and in secondary prevention of ischemic stroke. Although the clinical effect of classic antiplatelet drugs, such as aspirin and clopidogrel, has been recognized, some ...
Pan LI, Yu-ying ZHOU
doaj  

Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction [PDF]

, 2017
Recent clinical data show that the risk of coronary thrombosis after antiplatelet drugs withdrawal is much higher than that of surgical bleeding if they are continued.
Chassot, P.-G, Delabays, A., Spahn, D. R.   +2 more
core  

Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome [PDF]

, 2019
© The Author(s) 2019. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the ...
Gorog, Diana A, Gue, Ying X, Kanji, Rahim, Srinivasan, Manivannan, Wellsted, David M, Wyatt, Solange   +5 more
core   +2 more sources

Time-trends and treatment gaps in the antithrombotic management of patients with atrial fibrillation after percutaneous coronary intervention: Insights from the CHUM AF-STENT Registry. [PDF]

, 2020
BACKGROUND: The management of atrial fibrillation and flutter (AF) patients undergoing percutaneous coronary intervention (PCI) has undergone a rapid recent evolution. In 2016, the Canadian Cardiovascular Society (CCS) published expert recommendations to
Boivin-Proulx, L-A, Camm, JA, Deneault-Marchand, A, Fox, KAA, Gobeil, F, Mansour, S, Matteau, A, Potter, BJ   +7 more
core   +1 more source

Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives

Advanced Science, EarlyView.
This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård, Tatiana Bobrova, Amalie Leinebø, Thibault Leray, Shayamita Ghosh, Lorena García‐Hevia, Chiara Puccinelli, Lorenzo Riccio, Jacopo Sorani, Davide Bonifazi, Julien Caumartin, Emmanuel Donnadieu, Florence Gazeau, Roland Hischier, Else Marit Inderberg, Mónica L. Fanarraga, Maria Loustau, Bernd Nowack, Sébastien Wälchli, Cécilia Ménard‐Moyon   +19 more
wiley   +1 more source

Real-practice thromboprophylaxis in atrial fibrillation [PDF]

, 2017
This retrospective observational study was based on databases of the Local Health Authority of Treviso, Italy. It evaluated the prevalence and the effectiveness of oral anticoagulation treatment (OAT) for the management of nonvalvular atrial fibrillation
Bettiol, Alessandra, Bolcato, Jenny, Chinellato, Alessandro, Deambrosis, Paola, Franchin, Giulia, Giusti, Pietro, Pellizzari, Michele, Pirolo, Roberta, Themistoclakis, Sakis   +8 more
core   +2 more sources

FGL2‐HDAC11 Drives Immunothrombosis via NETs‐Mediated Endothelial Capillarization in MASLD Fibrosis

Advanced Science, EarlyView.
ABSTRACT Metabolic dysfunction–associated steatotic liver disease (MASLD) is frequently accompanied by hepatic fibrosis and systemic cardiovascular complications; however, the mechanistic interplay between coagulation abnormalities and disease progression remains poorly defined.
Xitang Li, Junjian Hu, Suping Hai, Peng Hu, Wenhui Wu, Qiang Gao, Binghui Yu, Feiyang Xu, Xizhe Zheng, Qianting Guan, Huiling Xiang, Dong Xi, Weiming Yan, Peng Wang, Bin‐hao Zhang, Qin Ning, Xiaojing Wang   +16 more
wiley   +1 more source